A new study details the completed, 14-patient pilot CTL019 trial, which began in mid 2010. Four CLL patients (29 percent) in the study achieved a complete remission. All the patients in this trial had CLL that had relapsed or continued to progress after receiving multiple conventional FDA approved therapies. (These patients were running out of options!) The link below provides a good but concise summary of the trial results based on information provided by the University of Pennsylvania School of Medicine: